HighTower Advisors LLC Acquires 37,269 Shares of Stryker Corporation $SYK

Key Points

• HighTower Advisors increased its Stryker stake by 8.3% in the second quarter, purchasing 37,269 additional shares to hold 486,005 shares valued at approximately $153 million. Institutional investors collectively own 77.09% of the company.
• Stryker reported quarterly earnings of $3.69 per share, exceeding the $3.49 consensus estimate, while revenue reached $6.59 billion, up 9.4% year over year.
• Analysts maintain a consensus “Moderate Buy” rating with an average price target of $386.28. Stryker also declared a quarterly dividend of $0.88 per share, representing a 1.0% annualized yield.

HighTower Advisors LLC raised its stake in shares of Stryker Corporation (NYSE:SYK - Free Report) by 8.3% in the second quarter, according to its most recent 13F filing with the SEC. The fund owned 486,005 shares of the medical technology company's stock after purchasing an additional 37,269 shares during the period. HighTower Advisors LLC owned approximately 0.13% of Stryker worth $153,014,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Varma Mutual Pension Insurance Co raised its position in Stryker by 10.5% in the 4th quarter. Varma Mutual Pension Insurance Co now owns 53,610 shares of the medical technology company's stock valued at $18,842,000 after buying an additional 5,100 shares during the last quarter. QRG Capital Management Inc. boosted its holdings in Stryker by 7.4% during the 4th quarter. QRG Capital Management Inc. now owns 60,548 shares of the medical technology company's stock worth $21,281,000 after acquiring an additional 4,186 shares during the last quarter. Swedbank AB boosted its holdings in Stryker by 6.6% during the 4th quarter. Swedbank AB now owns 129,027 shares of the medical technology company's stock worth $45,349,000 after acquiring an additional 7,934 shares during the last quarter. Crossmark Global Holdings Inc. grew its stake in shares of Stryker by 31.1% in the 4th quarter. Crossmark Global Holdings Inc. now owns 26,820 shares of the medical technology company's stock worth $9,426,000 after acquiring an additional 6,367 shares in the last quarter. Finally, Royal Bank of Canada raised its holdings in shares of Stryker by 6.5% in the first quarter. Royal Bank of Canada now owns 3,273,232 shares of the medical technology company's stock valued at $1,075,552,000 after purchasing an additional 199,863 shares during the last quarter. 77.09% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

SYK has been the topic of a number of recent analyst reports. Wall Street Zen raised shares of Stryker from a "hold" rating to a "buy" rating in a research report on Saturday, August 8th. The Goldman Sachs Group reiterated a "neutral" rating and issued a $361.00 price objective on shares of Stryker in a research note on Friday, May 1st. Wolfe Research cut shares of Stryker from an "outperform" rating to a "peer perform" rating in a research report on Thursday. Barclays cut their target price on Stryker from $469.00 to $394.00 and set an "overweight" rating on the stock in a research note on Monday, May 4th. Finally, JPMorgan Chase & Co. decreased their price target on Stryker from $400.00 to $350.00 and set an "overweight" rating for the company in a research report on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $386.28.

Stryker Price Performance

Shares of NYSE:SYK opened at $338.80 on Friday. The company has a market capitalization of $129.95 billion, a P/E ratio of 35.11, a price-to-earnings-growth ratio of 2.16 and a beta of 0.76. The company's 50-day moving average is $324.61 and its 200 day moving average is $333.57. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16. Stryker Corporation has a fifty-two week low of $281.00 and a fifty-two week high of $396.86.

Stryker (NYSE:SYK - Get Free Report) last released its earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, beating analysts' consensus estimates of $3.49 by $0.20. The firm had revenue of $6.59 billion during the quarter, compared to the consensus estimate of $6.58 billion. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The company's revenue was up 9.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, equities research analysts forecast that Stryker Corporation will post 15.02 earnings per share for the current year.

Stryker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be given a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 1.0%. The ex-dividend date of this dividend is Wednesday, September 30th. Stryker's dividend payout ratio (DPR) is currently 36.48%.

Insider Buying and Selling at Stryker

In other news, VP Robert S. Fletcher sold 4,544 shares of the stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the completion of the transaction, the vice president owned 10,582 shares in the company, valued at approximately $3,247,298.34. This represents a 30.04% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ronda E. Stryker sold 310,000 shares of Stryker stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total value of $96,791,300.00. Following the completion of the sale, the director directly owned 1,924,880 shares of the company's stock, valued at approximately $601,005,282.40. This trade represents a 13.87% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 4.60% of the company's stock.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source